Pfizer Inc. which can be found using ticker (PFE) now have 21 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $68.94 and $29.42 and has a mean target at $36.86. Now with the previous closing price of $30.19 and the analysts are correct then we can expect a percentage increase in value of 22.1%. Also worth taking note is the 50 day moving average now sits at $32.06 and the 200 day MA is $37.06. The market capitalization for the company is 168.09B. The stock price for the company is currently $29.77 USD
The potential market cap would be $205,231,242,759 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 16.27, revenue per share of $12.16 and a 2.39% return on assets.
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
